Fibrinogen deficiency is compatible with the development of atherosclerosis in mice

Journal of Clinical Investigation

Volumn 101, Issue 5, 1998, Pages 1184-1194

  Xiao, Qing ^a   Danton, Mary Jo S ^a   Witte, David P ^a   Kowala, Mark C ^b   Valentine, Maria T ^b   Degen, Jay L ^a  

^a CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

Apolipoprotein E; Atherosclerosis; Fibrin degradation; Fibrinogen; Products

Indexed keywords

APOLIPOPROTEIN E; CHOLESTEROL; FIBRINOGEN; FIBRINOGEN DEGRADATION PRODUCT; FIBRINOLYTIC FACTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PROCOAGULANT; TRIACYLGLYCEROL;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; BLOOD CLOTTING; CROSSING OVER; FIBRINOGEN DEFECT; FIBRINOLYSIS; GENOTYPE; HISTOPATHOLOGY; LIPID METABOLISM; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

EID: 0032030912     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI1461     Document Type: Article

References (47)

1. Schwartz, C.J., A.J. Valente, J.L. Kelley, E.A. Sprague, and E.H. Edwards. 1988. Thrombosis and the development of atherosclerosis: Rokitansky revisited. Semin. Thromb. Hemostasis. 14:189-195.
2. Fuster, V., L. Badimon, J.J. Badimon, and J.H. Chesebro. 1992. The pathogenesis of coronary artery disease and the acute coronary syndromes. N. Engl. J. Med. 326:242-250.
3. von Rokitansky, C. 1852. Abnormal conditions of the arteries. In A Manual of Pathological Anatomy. Sydenham Society. London. 261-275.
4. Bini, A., and B.J. Kudryk. 1995. Fibrinogen in human atherosclerosis. Ann. NY Acad. Sci. 748:461-471.
5. Bini, A., J.J. Fenoglio, Jr., R. Mesa-Tejada, B. Kudryk, and K.L. Kaplan. 1989. Identification and distribution of fibrinogen, fibrin, and fibrin(ogen) degradation products in atherosclerosis. Use of monoclonal antibodies. Arteriosclerosis. 9:109-121.
6. Wilcox, J.N., K.M. Smith, S.M. Schwartz, and D. Gordon. 1989. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc. Natl. Acad. Sci. USA. 86:2839-2843.
7. Schneiderman, J., M.S. Sawdey, M.R. Keeton, G.M. Bordin, E.F. Bernstein, R.B. Dilley, and D.J. Loskutoff. 1992. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc. Natl. Acad. Sci. USA. 89:6998-7002.
8. Lupu, F., D.A. Heim, F. Bachmann, M. Hurni, V.V. Kakkar, and E.K. Kruithof. 1995. Plasminogen activator expression in human atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 15:1444-1455.
9. Robbie, L.A., N.A. Booth, A.J. Brown, and B. Bennett. 1996. Inhibitors of fibrinolysis are elevated in atherosclerotic plaque. Arterioscler. Thromb. Vasc. Biol. 16:539-545.
10. Ernst, E., and K.L. Resch. 1993. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann. Intern. Med. 118:956-963.
11. Hamsten, A., P. Eriksson, F. Karpe, and A. Silveira. 1994. Relationships of thrombosis and fibrinolysis to atherosclerosis. Curr: Opin. Lipidol. 5:382-389.
12. Meade, T.W., S. Mellows, M. Brozovic, G.J. Miller, R.R. Chakrabarti, W.R. North, A.P. Haines, Y. Stirling, J.D. Imeson, and S.G. Thompson. 1986. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet. 2:533-537.
13. Naski, M.C., and J.A. Shafer. 1991. A kinetic model for the α-thrombincatalyzed conversion of plasma levels of fibrinogen to fibrin in the presence of antithrombin III. J. Biol. Chem. 266:13003-13010.
14. McDonagh, J., and M.H. Lee. 1997. How does hyperfibrinogenemia lead to thrombosis? Fibrinolysis & Proteolysis. 11(Suppl. 1):13-17.
15. Falk, E., and A. Fernandez-Ortiz. 1995. Role of thrombosis in atherosclerosis and its complications. Am. J. Cardiol. 75:3B-11B.
16. Languino, L.R., J. Plescia, A. Duperray, A.A. Brian, E.F. Plow, J.E. Geltosky, and D.C. Altieri. 1993. Fihrinogen mediates leukocyte adhesion to vascular endothelium through an ICAM-1-dependent pathway. Cell. 73:1423-1434.
17. Katagiri, Y., T. Hiroyama, N. Akamatsu, H. Suzuki, H. Yamazaki, and K. Tanoue. 1995. Involvement of αvβ3 integrin in mediating fibrin gel retraction. J. Biol. Chem. 270:1785-1790.
18. Naito, M., H. Nomura, and A. Iguchi. 1996. Migration of cultured vascular smooth muscle cells into non-crosslinked fibrin gels. Thromb. Res. 84:129-136.
19. Languino, L.R., A. Duperray, K.J. Joganic, M. Fornaro, G.B. Thornton, and D.C. Altieri. 1995. Regulation of leukocyte-endothelium interaction and leukocyte transendothelial migration by intercellular adhesion molecule 1-fibrin-ogen recognition. Proc. Natl. Acad. Sci. USA. 92:1505-1509.
20. Stirk, C.M., A. Kochhar, E.B. Smith, and W.D. Thompson. 1993. Presence of growth-stimulating fibrin degradation products containing fragment E in human atherosclerotic plaques. Atherosclerosis. 103:159-169.
21. Thompson, W.D., E.B. Smith, C.M. Stirk, and J. Wang. 1993. Fibrin degradation products in growth stimulatory extracts of pathological lesions. Blood Coagul. Fibrinolysis. 4:113-115.
22. Thompson, W.D., E.B. Smith, C.M. Stirk, F.I. Marshall, A.J. Stout, and A. Kocchar. 1992. Angiogenic activity of fibrin degradation products is located in fibrin fragment E. J. Pathol. 168:47-53.
23. Breslow, J.L. 1996. Mouse models of atherosclerosis. Science. 272:685-688.
24. Suh, T.T., K. Holmbäck, N.J. Jensen, C.C. Daugherty, K. Small, D.I. Simon, S. Potter, and J.L. Degen. 1995. Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice. Genes Dev. 9: 2020-2033.
25. Bugge, T.H., M.J. Flick, C.C. Daugherty, and J.L. Degen. 1995. Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Dev. 9:794-807.
26. Carmeliet, P., L. Schoonjans, L. Kieckens, B. Ream, J. Degen, R. Bronson, R. De Vos, J.J. van den Oord, D. Collen, and R.C. Mulligan. 1994. Physiological consequences of loss of plasminogen activator gene function in mice. Nature. 368:419-424.
27. Nakashima, Y., A.S. Plump, E.W. Raines, J.L. Breslow, and R. Ross. 1994. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler. Thromb. 14:133-140.
28. Reddick, R.L., S.H. Zhang, and N. Maeda. 1994. Atherosclerosis in mice lacking apo E. Evaluation of lesional development and progression. Arterioscler. Thromb. 14:141-147.
29. Plump, A.S., J.D. Smith, T. Hayek, K. Aalto-Setala, A. Walsh, J.G. Verstuyft, E.M. Rubin, and J.L. Breslow. 1992. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 71:343-353.
30. Horiuchi, K., S. Tajima, M. Menju, and A. Yamamoto. 1989. Structure and expression of mouse apolipoprotein E gene. J. Biochem. (Tokyo). 106:98-103.
31. Bugge, T.H., K.W. Kombrinck, M.J. Flick, C.C. Daugherty, M.J. Danton, and J.L. Degen. 1996. Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen deficiency. Cell. 87:709-719.
32. Paigen, B., A. Morrow, P.A. Holmes, D. Mitchell, and R.A. Williams. 1987. Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis. 68:231-240.
33. Lawn, R.M., O.P. Wade, R.E. Hammer, G. Chiesa, J.G. Verstuyft, and E.M. Rubin. 1992. Atherogenesis in transgenic mice expressing human apolipoprotein(a). Nature. 360:670-672.
34. Zhang, S.H., R.L. Reddick, J.A. Piedrahita, and N. Maeda. 1992. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 258:468-471.
35. Ishibashi, S., J.L. Goldstein, M.S. Brown, J. Herz, and O.K. Burns. 1994. Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice. J. Clin. lnvest. 93:1885-1893.
36. Chiesa, G., H.H. Hobbs, M.L. Koschinsky, R.M. Lawn, S.D. Maika, and R.E. Hammer. 1992. Reconstitution of lipoprotein(a) by infusion of human low density lipoprotein into transgenic mice expressing human apolipoprotein(a). J. Biol. Chem. 267:24369-24374
37. Scanu, A.M., R.M. Lawn, and K. Berg. 1991. Lipoprotein(a) and atherosclerosis. Ann. Intern. Med. 115:209-218.
38. Hajjar, K.A., D. Gavish, J.L. Breslow, and R.L. Nachman. 1989. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature. 339:303-305.
39. Harpel, P.C., B.R. Gordon, and T.S. Parker. 1989. Plasmin catalyzes binding of lipoprotein (a) to immobilized fibrinogen and fibrin. Proc. Natl. Acad. Sci. USA. 86:3847-3851.
40. Rouy, D., P. Grailhe, F. Nigon, J. Chapman, and E. Angles-Cano. 1991. Lipoprotein(a) impairs generation of plasmin by fibrin-bound tissue-type plasminogen activator. In vitro studies in a plasma milieu. Arterioscler. Thromb. 11: 629-638.
41. Xiao, Q., M.J.S. Danton, D.P. Witte, M.C. Kowala, M.T. Valentine, T.H. Bugge, and J.L. Degen. 1997. Plasminogen deficiency accelerates vessel wall disease in mice predisposed to atherosclerosis. Proc. Natl. Acad. Sci. USA. 94:10335-10340.
42. Grainger, D.J., P.R. Kemp, A.C. Liu, R.M. Lawn, and J.C. Metcalfe. 1994. Activation of transforming growth factor-β is inhibited in transgenic apolipoprotein(a) mice. Nature. 370:460-462.
43. Grainger, D.J., L. Wakefield, H.W. Bethell, R. W. Farndale, and J.C. Metcalfe. 1995. Release and activation of platelet latent TGF-β in blood clots during dissolution with plasmin. Nat. Med. 1:932-937.
44. Odekon, L.E., F. Blasi, and D.E. Rifkin. 1994. Requirement for receptor-bound urokinase in plasmin-dependent cellular conversion of latent TGF-β to TGF-β. J. Cell Physiol. 158:398-407.
45. Moran, C.S., J.H. Campbell, D.L. Simmons, and G.R. Campbell. 1994. Human leukemia inhibitory factor inhibits development of experimental atherosclerosis. Arterioscler. Thromb. 14:1356-1363.
46. Carmeliet, P., L. Moons, V. Ploplis, E. Plow, and D. Collen. 1997. Impaired arterial neointima formation in mice with disruption of the plasminogen gene. J. Clin. Invest. 99:200-208.
47. Lindner, V., J. Fingerle, and M.A. Reidy. 1993. Mouse model of arterial injury. Circ. Res. 73:792-796.